Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merck & (MRK)

Merck names Paul J. Diaz to board effective Nov. 1, 2026

Neutral Impact 2 of 5 leadership Written later

Merck & Co. said Paul J. Diaz, managing partner at Cressey & Company, will join its Board of Directors effective Nov. 1, 2026, bringing the board to 14 members. He will stand for election by shareholders in May 2027 and will serve on the Audit and Research Committees, and he will be paid as a non-employee director under the company's published compensation practices.

Key points

  • Diaz joins the board effective Nov. 1, 2026, and will stand for shareholder election in May 2027.
  • He was appointed to both the Audit Committee and the Research Committee.
  • The board will have 14 members after his addition.
  • Diaz previously served as president and CEO of Myriad Genetics, Inc. and Kindred Healthcare.

The filing

CompanyMerck & (MRK)
Form8-K, current report
Filed with the SECOct 13, 2026, 12:36 PM ET
Accession number0000310158-26-000237

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.